Company profile
Epitopea Limited
Home - Epitopea
Epitopea Limited is a UK company with status active founded in 2021 based in East of England.
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzUyMzY3ODU0M2FkaXF6a2N4
Published 27 May 2026 09:52
Change Person Director Company With Change Date
OfficersCH01 | Transaction MzUyMzI1MzgwOWFkaXF6a2N4
Published 22 May 2026 10:36
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Capital Allotment Shares
CapitalSH01 | Transaction MzQ1NjE3NjY4N2FkaXF6a2N4
Published 24 Feb 2025 04:22
Capital Allotment Shares
CapitalSH01 | Transaction MzQ0MTYyNjQ0NGFkaXF6a2N4
Published 31 Oct 2024 03:03
Capital Allotment Shares
CapitalSH01 | Transaction MzQzNzU0MTIzM2FkaXF6a2N4
Published 27 Sep 2024 02:36
Capital Name Of Class Of Shares
CapitalSH08 | Transaction MzQzMTk2MzUwN2FkaXF6a2N4 | Paper/PDF filed
Published 16 Aug 2024 12:40
Capital Allotment Shares
CapitalSH01 | Transaction MzQzMTcxMTQ0MWFkaXF6a2N4
Published 09 Aug 2024 10:33
Memorandum Articles
IncorporationMA | Transaction MzQzMTE2NjcyOGFkaXF6a2N4 | Paper/PDF filed
Published 09 Aug 2024 10:00
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Combining therapeutic vaccines and TCR-based therapeutics directed against novel antigens presented by cancer associated fibroblasts
1 Aug 2024 to 30 Apr 2026
Vaccines have proven to be been humanity's most effective medical intervention acting to prepare or stimulate an immune system against the desired target. The approach has delivered generally excellent safety profiles, has a broad potential to treat a range of diseases and modern iterations of the technology (namely LNP-mRNA vaccines) have highly flexible...
Accelerating the manufacture of RNA therapies
1 Nov 2023 to 31 Jan 2025
RNA therapeutics will change the standard of care for many diseases, transitioning from rare to chronic diseases, and actualize personalized medicine for millions of patients. Demand for flexible cGMP manufacturing will significantly increase across multiple RNA-therapy modalities to accelerate their route-to-patient and improve their economics. However, ...